CY1112337T1 - Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου - Google Patents

Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου

Info

Publication number
CY1112337T1
CY1112337T1 CY20111100570T CY111100570T CY1112337T1 CY 1112337 T1 CY1112337 T1 CY 1112337T1 CY 20111100570 T CY20111100570 T CY 20111100570T CY 111100570 T CY111100570 T CY 111100570T CY 1112337 T1 CY1112337 T1 CY 1112337T1
Authority
CY
Cyprus
Prior art keywords
sulfonamido
acetamide
amyloid peptide
inhibitor
production
Prior art date
Application number
CY20111100570T
Other languages
Greek (el)
English (en)
Inventor
Jr John E Starrett
Kevin W Gillman
Richard E Olson
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112337(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1112337T1 publication Critical patent/CY1112337T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20111100570T 2007-10-31 2011-06-15 Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου CY1112337T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
EP08843687A EP2205575B1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
CY1112337T1 true CY1112337T1 (el) 2015-12-09

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100570T CY1112337T1 (el) 2007-10-31 2011-06-15 Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου
CY20121100889T CY1113346T1 (el) 2007-10-31 2012-09-28 Καινοφανη ενδιαμεσα προϊοντα χρησιμα στην παρασκευη της ενωσης του αλφα-(ν-σουλφοναμιδο)ακεταμιδιου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100889T CY1113346T1 (el) 2007-10-31 2012-09-28 Καινοφανη ενδιαμεσα προϊοντα χρησιμα στην παρασκευη της ενωσης του αλφα-(ν-σουλφοναμιδο)ακεταμιδιου

Country Status (28)

Country Link
US (2) US8084477B2 (enExample)
EP (3) EP2295417B1 (enExample)
JP (1) JP5460605B2 (enExample)
KR (1) KR20100075575A (enExample)
CN (2) CN102718689A (enExample)
AR (1) AR069135A1 (enExample)
AT (1) ATE502022T1 (enExample)
AU (1) AU2008319122A1 (enExample)
BR (1) BRPI0818837A2 (enExample)
CA (1) CA2704360A1 (enExample)
CL (1) CL2008003271A1 (enExample)
CO (1) CO6270332A2 (enExample)
CY (2) CY1112337T1 (enExample)
DE (1) DE602008005636D1 (enExample)
DK (2) DK2205575T3 (enExample)
EA (2) EA201171439A1 (enExample)
ES (2) ES2361283T3 (enExample)
HR (2) HRP20110219T1 (enExample)
IL (1) IL205406A0 (enExample)
MX (1) MX2010004319A (enExample)
NZ (1) NZ584545A (enExample)
PE (1) PE20091394A1 (enExample)
PL (2) PL2295417T3 (enExample)
PT (2) PT2295417E (enExample)
SG (2) SG174043A1 (enExample)
SI (2) SI2205575T1 (enExample)
TW (1) TW200927099A (enExample)
WO (1) WO2009058552A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
MX2011009271A (es) * 2009-03-19 2011-09-26 Bristol Myers Squibb Co Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide.
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
CN104072408B (zh) * 2010-03-12 2016-09-14 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
EP2643299B1 (en) * 2010-11-22 2016-06-22 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
JP2015529250A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ フルオロアルキルジベンゾジアゼピノン化合物
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
WO2014047369A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
RU2757276C2 (ru) 2016-12-16 2021-10-12 Пайплайн Терапьютикс, Инк. Способы лечения кохлеарной синаптопатии
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
MX2020012495A (es) 2018-06-01 2021-02-15 Novartis Ag Moleculas de union contra bcma y usos de las mismas.
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
TW202115114A (zh) 2019-06-24 2021-04-16 瑞士商諾華公司 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
PL326700A1 (en) 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
RU2202540C2 (ru) 1996-07-22 2003-04-20 Монсанто Компани Тиолсульфонамидные ингибиторы металлопротеазы
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
NZ512306A (en) 1999-01-27 2003-10-31 American Cyanamid Co Acetylenic sulfonamide thiol tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
EP1159263A1 (en) * 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
US20040179277A1 (en) * 2001-12-14 2004-09-16 Stallard Charles R Precisely aligned lens structure and a method for its fabrication
ATE430727T1 (de) 2001-12-20 2009-05-15 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta- amyloidinhibitoren
PL372090A1 (en) * 2002-02-28 2005-07-11 Astrazeneca Ab Chemical compounds
ES2286345T3 (es) * 2003-03-20 2007-12-01 Santhera Pharmaceuticals (Schweiz) Ag Derivados de piperidina y piperazina substituidos como moduladores del receptor de melanocortina-4.
JP2006522126A (ja) 2003-03-31 2006-09-28 ワイス βアミロイド生産のフルオロ含有およびトリフルオロアルキル含有複素環スルホンアミド阻害物質およびその誘導体
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
BRPI0707742A2 (pt) 2006-02-17 2011-05-10 Wyeth Corp processo para preparar um composto
US7687666B2 (en) 2006-02-17 2010-03-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
EP2295417B1 (en) 2012-07-04
US8350084B2 (en) 2013-01-08
CY1113346T1 (el) 2016-06-22
CN101910141B (zh) 2012-12-19
EP2205575B1 (en) 2011-03-16
JP5460605B2 (ja) 2014-04-02
PT2205575E (pt) 2011-05-23
EA016447B1 (ru) 2012-05-30
SG174044A1 (en) 2011-09-29
EA201171439A1 (ru) 2012-05-30
CN102718689A (zh) 2012-10-10
CN101910141A (zh) 2010-12-08
CL2008003271A1 (es) 2009-07-10
EP2471769A1 (en) 2012-07-04
PL2295417T3 (pl) 2012-11-30
SI2205575T1 (sl) 2011-07-29
US20120088925A1 (en) 2012-04-12
IL205406A0 (en) 2010-12-30
DK2295417T3 (da) 2012-10-15
AU2008319122A1 (en) 2009-05-07
EA201000714A1 (ru) 2010-10-29
CA2704360A1 (en) 2009-05-07
DE602008005636D1 (de) 2011-04-28
ATE502022T1 (de) 2011-04-15
HRP20120703T1 (hr) 2012-09-30
TW200927099A (en) 2009-07-01
JP2011502153A (ja) 2011-01-20
KR20100075575A (ko) 2010-07-02
ES2390042T3 (es) 2012-11-06
MX2010004319A (es) 2010-04-30
BRPI0818837A2 (pt) 2015-04-22
HK1141801A1 (en) 2010-11-19
SI2295417T1 (sl) 2012-11-30
EP2205575A1 (en) 2010-07-14
PT2295417E (pt) 2012-09-26
CO6270332A2 (es) 2011-04-20
WO2009058552A1 (en) 2009-05-07
SG174043A1 (en) 2011-09-29
PE20091394A1 (es) 2009-09-25
HRP20110219T1 (hr) 2011-04-30
EP2295417A1 (en) 2011-03-16
ES2361283T3 (es) 2011-06-15
HK1155161A1 (en) 2012-05-11
US20090111858A1 (en) 2009-04-30
NZ584545A (en) 2011-04-29
PL2205575T3 (pl) 2011-09-30
AR069135A1 (es) 2009-12-30
US8084477B2 (en) 2011-12-27
DK2205575T3 (da) 2011-07-11

Similar Documents

Publication Publication Date Title
CY1112337T1 (el) Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου
CY1122861T1 (el) Φαρμακευτικες συνθεσεις της αμορφης μορφης ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
NO20083598L (no) Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase
GT200600432A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la beta-secretasa
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
UY29636A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
CL2008001960A1 (es) Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
MA31564B1 (fr) Inhibition par arni de l'expression du canal alpha-enac
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
EA201291413A1 (ru) Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
CY1120846T1 (el) 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1
GT201000045A (es) Derivados de ciclopropilamida '978
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
MX385354B (es) Sales de xantilio 3,6-disustituidas.
PA8601001A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
CL2008002394A1 (es) Depsipeptido ciclico, o derivados, inhibidores de calicreína 7, obtenidos desde chondromyces crocatus, metodo de obtencion y usos terapeuticos.
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
AR050717A1 (es) Composiciones farmaceuticas
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
MX2021007505A (es) Síntesis de 3-metil-1,2,4-tiadiazol-5-carbohidrazida o de su forma deuterada con metil-d3.